PDF herunterladen
Semin Neurol 2025; 45(02): 298-302
DOI: 10.1055/a-2544-1530
Review Article

Emerging Genetic Therapies in Epilepsy

Joseph Sullivan 
1   Department of Neurology, University of California San Francisco, San Francisco, California
,
Veronica Hood 
2   Epilepsy Division, Dravet Syndrome Foundation, Cherry Hill, New Jersey
› Institutsangaben
› Weitere Informationen
    Lizenzen und Reprints

Abstract

Advances in next-generation sequencing have allowed for genetic characterization of many epilepsies that previously had no known cause. Although having a precise diagnosis has been very helpful for management, counseling, and prognosis, until recently true precision medicine approaches that could have disease-modifying effects have been lacking. This review will highlight how preclinical animal models of Dravet syndrome have allowed some novel gene therapy approaches to be studied and further developed such that they are now entering into the clinics.

Keywords

epilepsy - gene therapy - Dravet syndrome - antisense oligonucleotide - ASO - AAV9


Publikationsverlauf

Accepted Manuscript online:
24. Februar 2025

Artikel online veröffentlicht:
24. März 2025

© 2025. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Berg AT, Coryell J, Saneto RP. et al. Early-life epilepsies and the emerging role of genetic testing. JAMA Pediatr 2017; 171 (09) 863-871
    CrossrefPubMedSuche in Google Scholar
  • 2 Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989; 30 (04) 389-399
    CrossrefPubMedSuche in Google Scholar
  • 3 Claes L, Del-Favero J, Ceulemans B, Lagae L, Van Broeckhoven C, De Jonghe P. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet 2001; 68 (06) 1327-1332
    CrossrefPubMedSuche in Google Scholar
  • 4 Li W, Schneider AL, Scheffer IE. Defining Dravet syndrome: an essential pre-requisite for precision medicine trials. Epilepsia 2021; 62 (09) 2205-2217
    CrossrefPubMedSuche in Google Scholar
  • 5 Cheah CS, Yu FH, Westenbroek RE. et al. Specific deletion of NaV1.1 sodium channels in inhibitory interneurons causes seizures and premature death in a mouse model of Dravet syndrome. Proc Natl Acad Sci U S A 2012; 109 (36) 14646-14651
    CrossrefPubMedSuche in Google Scholar
  • 6 Lersch R, Jannadi R, Grosse L. et al. Targeted molecular strategies for genetic neurodevelopmental disorders: emerging lessons from Dravet syndrome. Neuroscientist 2023; 29 (06) 732-750
    CrossrefPubMedSuche in Google Scholar
  • 7 Mavashov A, Brusel M, Liu J. et al. Heat-induced seizures, premature mortality, and hyperactivity in a novel Scn1a nonsense model for Dravet syndrome. Front Cell Neurosci 2023; 17: 1149391
    CrossrefPubMedSuche in Google Scholar
  • 8 Claes LR, Deprez L, Suls A. et al. The SCN1A variant database: a novel research and diagnostic tool. Hum Mutat 2009; 30 (10) E904-E920
    CrossrefPubMedSuche in Google Scholar
  • 9 Meng H, Xu HQ, Yu L. et al. The SCN1A mutation database: updating information and analysis of the relationships among genotype, functional alteration, and phenotype. Hum Mutat 2015; 36 (06) 573-580
    CrossrefPubMedSuche in Google Scholar
  • 10 Yu FH, Mantegazza M, Westenbroek RE. et al. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci 2006; 9 (09) 1142-1149
    CrossrefPubMedSuche in Google Scholar
  • 11 Martin MS, Dutt K, Papale LA. et al. Altered function of the SCN1A voltage-gated sodium channel leads to gamma-aminobutyric acid-ergic (GABAergic) interneuron abnormalities. J Biol Chem 2010; 285 (13) 9823-9834
    CrossrefPubMedSuche in Google Scholar
  • 12 Yamagata T, Raveau M, Kobayashi K. et al. CRISPR/dCas9-based Scn1a gene activation in inhibitory neurons ameliorates epileptic and behavioral phenotypes of Dravet syndrome model mice. Neurobiol Dis 2020; 141: 104954
    CrossrefPubMedSuche in Google Scholar
  • 13 Tanenhaus A, Stowe T, Young A. et al. Cell-selective adeno-associated virus-mediated SCN1A gene regulation therapy rescues mortality and seizure phenotypes in a Dravet syndrome mouse model and is well tolerated in nonhuman primates. Hum Gene Ther 2022; 33 (11-12): 579-597
    CrossrefPubMedSuche in Google Scholar
  • 14 Ricobaraza A, Bunuales M, Gonzalez-Aparicio M. et al. Preferential expression of SCN1A in GABAergic neurons improves survival and epileptic phenotype in a mouse model of Dravet syndrome. J Mol Med (Berl) 2023; 101 (12) 1587-1601
    CrossrefPubMedSuche in Google Scholar
  • 15 Mich JK, Ryu J, Wei AD. et al. AAV-mediated interneuron-specific gene replacement for Dravet syndrome. bioRxiv 2023
    PubMedSuche in Google Scholar
  • 16 Favero M, Sotuyo NP, Lopez E, Kearney JA, Goldberg EM. A transient developmental window of fast-spiking interneuron dysfunction in a mouse model of Dravet syndrome. J Neurosci 2018; 38 (36) 7912-7927
    CrossrefPubMedSuche in Google Scholar
  • 17 Goff KM, Goldberg EM. Vasoactive intestinal peptide-expressing interneurons are impaired in a mouse model of Dravet syndrome. eLife 2019; 8: 8
    CrossrefPubMedSuche in Google Scholar
  • 18 Mattis J, Somarowthu A, Goff KM. et al. Corticohippocampal circuit dysfunction in a mouse model of Dravet syndrome. eLife 2022; 11: 11
    CrossrefPubMedSuche in Google Scholar
  • 19 Goff KM, Liebergall SR, Jiang E, Somarowthu A, Goldberg EM. VIP interneuron impairment promotes in vivo circuit dysfunction and autism-related behaviors in Dravet syndrome. Cell Rep 2023; 42 (06) 112628
    CrossrefPubMedSuche in Google Scholar
  • 20 Mora-Jimenez L, Valencia M, Sanchez-Carpintero R. et al. Transfer of SCN1A to the brain of adolescent mouse model of Dravet syndrome improves epileptic, motor, and behavioral manifestations. Mol Ther Nucleic Acids 2021; 25: 585-602
    CrossrefPubMedSuche in Google Scholar
  • 21 Fadila S, Beucher B, Dopeso-Reyes IG. et al. Viral vector-mediated expression of NaV1.1, after seizure onset, reduces epilepsy in mice with Dravet syndrome. J Clin Invest 2023; 133 (12) 133
    CrossrefPubMedSuche in Google Scholar
  • 22 Lim KH, Han Z, Jeon HY. et al. Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression. Nat Commun 2020; 11 (01) 3501
    CrossrefPubMedSuche in Google Scholar
  • 23 Kaneko K, Currin CB, Goff KM. et al. Developmentally regulated impairment of parvalbumin interneuron synaptic transmission in an experimental model of Dravet syndrome. Cell Rep 2022; 38 (13) 110580
    CrossrefPubMedSuche in Google Scholar
  • 24 Jones SP, O'Neill N, Carpenter JC. et al. Early developmental alterations of CA1 pyramidal cells in Dravet syndrome. Neurobiol Dis 2024; 201: 106688
    CrossrefPubMedSuche in Google Scholar
  • 25 Di Berardino C, Mainardi M, Brusco S, Benvenuto E, Broccoli V, Colasante G. Temporal manipulation of the Scn1a gene reveals its essential role in adult brain function. Brain 2024; 147 (04) 1216-1230
    CrossrefPubMedSuche in Google Scholar
  • 26 Valassina N, Brusco S, Salamone A. et al. Scn1a gene reactivation after symptom onset rescues pathological phenotypes in a mouse model of Dravet syndrome. Nat Commun 2022; 13 (01) 161
    CrossrefPubMedSuche in Google Scholar
  • 27 Han Z, Chen C, Christiansen A. et al. Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome. Sci Transl Med 2020; 12 (558) 12
    CrossrefPubMedSuche in Google Scholar
  • 28 Wengert ER, Wagley PK, Strohm SM. et al. Targeted Augmentation of Nuclear Gene Output (TANGO) of Scn1a rescues parvalbumin interneuron excitability and reduces seizures in a mouse model of Dravet syndrome. Brain Res 2022; 1775: 147743
    CrossrefPubMedSuche in Google Scholar
  • 29 Meena M, Ticho B, Mohapatra S, Barriere O, Gosselin N. A pharmacokinetic (PK) model for STK-001, an antisense oligonucleotide (ASO), based on data from non-human primates (NHP) enables dose selection in patients with Dravet syndrome (DS). 2021
    PubMedSuche in Google Scholar
  • 30 Laux LCJ, Sullivan J, Desurkar A, Roberts CM, Schreiber JM, Knupp KG, Perry MS, Wheless JM, Wirrell EC, Brathwaite C, Condon C, Dandurand A, Lynch J, Stutely J, Wang F, Parkerson KA, Ticho B. Zorevunersen (STK-001) demonstrates potential for disease modification including reductions in seizures and improvements in cognition and behavior in children and adolescents with Dravet syndrome. 2024
    PubMedSuche in Google Scholar
  • 31 Sullivan J, Brunklaus A, Cross JH. et al. Patients with Dravet Syndrome in Open-label Extension Studies of Zorevunersen (STK-001) Have Durable Reductions in Seizure Frequency and Clinically Meaningful Improvements in Cognition and Behavior. 2024
    PubMedSuche in Google Scholar
  • 32 Condon CParkerson K, Dandurand A. et al. Small Changes on the vineland-3 are meaningful to caregivers of patients with Dravet syndrome. 2023
    PubMedSuche in Google Scholar
  • 33 Sullivan J, Deighton AM, Vila MC. et al. The clinical, economic, and humanistic burden of Dravet syndrome—a systematic literature review. Epilepsy Behav 2022; 130: 108661
    CrossrefPubMedSuche in Google Scholar